KETOPROFEN (ORUDIS) IN THE TREATMENT OF JUVENILE RHEUMATOID-ARTHRITIS - A SEGMENT-I STUDY

  • 1 January 1982
    • journal article
    • research article
    • Vol. 9  (1) , 144-148
Abstract
A safe and efficacious dose of ketoprofen was established in children with JRA [juvenile rheumatoid arthritis] during a 4-wk, open-labeled, non-controlled trial. Initial dosage was 100 mg/m2 per day gradually increased up to 200 mg/m2 per day, not to exceed 320 mg/day. One patient was removed from the study due to hematuria. Clinical improvement was observed in .gtoreq. 50% of the patients in 8 of the 15 indices assessed. Statistical improvement was detected in the number and severity of joints with pain on motion, the duration of morning stiffness/ and the time required to travel 50 feet (P < 0.035). Significant laboratory changes included decreases in the mean Hb and hematocrit, and increases in erthryocyte sedimentation rate and blood urea N (P < 0.03). Twenty patients experienced a total of 39 adverse effects, and of these 6 were judged to be attributable to ketoprofen. Evidently, ketoprofen''s efficacy and safety is comparable to that of other nonsteroidal antiinflammatory drugs.